Jurgen H. Finke

Hugstetter Str. 55
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 323 publications

Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.

Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.

Journal: Transplantation and cellular therapy

Published: May 08, 2026

Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis.

Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis.

Journal: Transplantation and cellular therapy

Published: May 08, 2026

Continued remission maintained with decitabine monotherapy in an elderly patient with TP53 multi-hit acute myeloid leukemia relapsed after allogeneic transplantation.

Continued remission maintained with decitabine monotherapy in an elderly patient with TP53 multi-hit acute myeloid leukemia relapsed after allogeneic transplantation.

Journal: Haematologica

Published: May 05, 2026

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: April 27, 2026

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Journal: Transfusion

Published: March 17, 2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Journal: Lancet (London, England)

Published: February 19, 2026

Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy.

Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy.

Journal: Annals of hematology

Published: January 27, 2026

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Journal: Annals of hematology

Published: December 13, 2025

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Journal: Bone marrow transplantation

Published: December 10, 2025

Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation.

Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation.

Journal: Frontiers in immunology

Published: November 13, 2025

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: September 19, 2025

Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study.

Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study.

Journal: Haematologica

Published: May 21, 2025

Showing 1-12 of 323

Last Updated: 09/26/2026